American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations
    Meeting Abstract

    George, S.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Achour, H.; Sherman, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy
    Meeting Abstract

    Riedel, R. F.; Chawla, S. P.; Druta, M.; Jones, R. L.s; Schuetze, S.; Lam, J.; Zhuang, D.; Freddo, J. L.; Adams, B. J.; Theuer, C. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator's choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy
    Meeting Abstract

    Lacuna, K. P.; Mandrekar, S. J.; Allred, J. B.; Berg, S. A.; Hensley, M. L.; Van Tine, B. A.; George, S.; Schwartz, G. K.; Ingham, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor
    Meeting Abstract

    Gelderblom, H.; Bhadri, V.; Randall, R. L.; Scharschmidt, T.; Tap, W. D.; Alani, L.; Johnson, K.; Leyva, S.; Nguyen, D. D.; Nguyen, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)
    Meeting Abstract

    Forde, P. M.; Nowak, A. K.; Hughes, B. G. M.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K.; Yip, S.; Cook, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001)
    Meeting Abstract

    Mansfield, A. S.; Goodrich, A.; Foster, N. R.; Savvides, P.; Villaruz, L. C.; Forde, P. M.; Raghav, K. P. S.; Romesser, P. B.; Feldman, D.; Cao, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies
    Meeting Abstract

    Rimner, A.; Huang, J.; Pagano, A.; Ginsberg, M. S.; Chang, J. C.; Riely, G. J.; Simone, C. B.; Gomez, D. R.; Shepherd, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer
    Meeting Abstract

    Johnson, M. L.; Henry, J. T.; Spira, A. I.; Battiste, J.; Alnahhas, I.; Ahluwalia, M. S.; Barve, M. A.; Edenfield, W. J.; Nam, D. H.; Eathiraj, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM)
    Meeting Abstract

    Davar, D.; Ikeguchi, A.; Buchbinder, E. I.; Shoushtari, A. N.; Seedor, R. S.; Bernicker, E.; Weiss, S. A.; Daniels, G. A.; Panella, T. J.; Ryan, H. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save